Vericel Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total net revenue increased 22% to $77.5 million, driven by a 23% rise in MACI revenue to $65.5 million and a 22% increase in Burn Care revenue to $12.0 million. The company achieved gross margins of 73%, net income of $2.2 million ($0.04 per diluted share), and free cash flow of $14.3 million. Vericel raised its full-year 2026 total revenue guidance to $330–$340 million from the previous range of $326–$336 million. Additionally, the Board authorized a new $200 million share repurchase program. The company operates in the advanced cell therapy and biologic markets, providing treatments for sports medicine injuries and severe burn care.